Symbols / ADCT $4.80 +13.48%
ADCT Chart
About
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 594.61M |
| Enterprise Value | 746.70M | Income | -166.94M | Sales | 75.21M |
| Book/sh | -2.12 | Cash/sh | 1.90 | Dividend Yield | — |
| Payout | 0.00% | Employees | 263 | IPO | — |
| P/E | — | Forward P/E | -3.22 | PEG | — |
| P/S | 7.91 | P/B | -2.27 | P/C | — |
| EV/EBITDA | -6.15 | EV/Sales | 9.93 | Quick Ratio | 4.15 |
| Current Ratio | 4.63 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.41 | EPS next Y | -1.49 | EPS Growth | — |
| Revenue Growth | -11.00% | Earnings | 2026-03-10 | ROA | -23.98% |
| ROE | — | ROIC | — | Gross Margin | -57.42% |
| Oper. Margin | -186.23% | Profit Margin | -221.97% | Shs Outstand | 123.88M |
| Shs Float | 97.69M | Short Float | 4.25% | Short Ratio | 6.45 |
| Short Interest | — | 52W High | 4.95 | 52W Low | 1.05 |
| Beta | 1.97 | Avg Volume | 901.67K | Volume | 1.56M |
| Target Price | $8.00 | Recom | Strong_buy | Prev Close | $4.23 |
| Price | $4.80 | Change | 13.48% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.00
Mean price target
2. Current target
$4.80
Latest analyst target
3. DCF / Fair value
$-12.68
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.80
Low
$6.00
High
$10.00
Mean
$8.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-16 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-08-13 | reit | Guggenheim | Buy → Buy | $10 |
| 2025-06-20 | main | RBC Capital | Outperform → Outperform | $5 |
| 2025-06-13 | main | Guggenheim | Buy → Buy | $10 |
| 2025-05-15 | reit | RBC Capital | Outperform → Outperform | $8 |
| 2025-03-31 | main | Guggenheim | Buy → Buy | $7 |
| 2025-03-31 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-03-07 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-02-24 | main | Stephens & Co. | Overweight → Overweight | $8 |
| 2025-01-06 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-12-12 | reit | Guggenheim | Buy → Buy | $10 |
| 2024-12-11 | reit | HC Wainwright & Co. | Buy → Buy | — |
| 2024-11-08 | init | Stephens & Co. | — → Overweight | $6 |
| 2024-08-08 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-08-07 | reit | RBC Capital | Outperform → Outperform | $8 |
| 2024-05-30 | init | Cantor Fitzgerald | — → Overweight | — |
| 2024-05-07 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-04-15 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-04-05 | reit | Guggenheim | — → Buy | — |
| 2024-03-28 | init | Guggenheim | — → Buy | $11 |
- Cancer drug maker ADC Therapeutics eyes 2026 trial results, funds into 2028 - Stock Titan ue, 10 Mar 2026 11
- ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q4 2025 Earnings - Quiver Quantitative ue, 10 Mar 2026 11
- ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance ue, 10 Mar 2026 12
- ADC Therapeutics (NYSE:ADCT) Shares Gap Up After Strong Earnings - MarketBeat ue, 10 Mar 2026 15
- ADC Therapeutics (ADCT) Loss Narrowing To US$0.04 EPS Challenges Bearish Profitability Narrative - simplywall.st ue, 10 Mar 2026 22
- ADC Therapeutics reports Q4 revenue of $22.3 million - Investing.com ue, 10 Mar 2026 13
- Should I hold or sell ADCT stock in 2026 - 2026 Chart Watch & High Accuracy Swing Trade Signals - Naître et grandir Sat, 07 Mar 2026 20
- ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement - PR Newswire Mon, 23 Feb 2026 08
- ADC Therapeutics Q4 Earnings Call Highlights - Yahoo Finance ue, 10 Mar 2026 15
- ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026 - Finviz Mon, 09 Mar 2026 12
- ADC Therapeutics (NYSE:ADCT) Posts Earnings Results, Beats Expectations By $0.23 EPS - MarketBeat ue, 10 Mar 2026 12
- Adc Thera earnings beat by $0.20, revenue topped estimates - Investing.com ue, 10 Mar 2026 12
- Why ADCT stock is a must watch in 2026 - 2026 Risk Factors & High Conviction Buy Zone Picks - Naître et grandir Sat, 07 Mar 2026 20
- ADC Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat ue, 10 Mar 2026 17
- Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance Wed, 17 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 294800 | 1176252 | — | Stock Award(Grant) at price 3.99 per share. | GRAHAM PETER J | Officer | — | 2026-02-13 00:00:00 | D |
| 1 | 271600 | 1083684 | — | Stock Award(Grant) at price 3.99 per share. | CARMONA JOSE | Chief Financial Officer | — | 2026-02-13 00:00:00 | D |
| 2 | 900000 | 3591000 | — | Stock Award(Grant) at price 3.99 per share. | MALLIK AMEET | Chief Executive Officer | — | 2026-02-13 00:00:00 | D |
| 3 | 285200 | 1137948 | — | Stock Award(Grant) at price 3.99 per share. | ZAKI MOHAMED | Officer | — | 2026-02-13 00:00:00 | D |
| 4 | 62900 | 250971 | — | Stock Award(Grant) at price 3.99 per share. | KALLEBO LISA MICHELLE | Officer | — | 2026-02-13 00:00:00 | D |
| 5 | 40000 | — | — | Stock Award(Grant) at price 0.00 per share. | COUGHLIN TIMOTHY P | Director | — | 2025-06-03 00:00:00 | D |
| 6 | 40000 | — | — | Stock Award(Grant) at price 0.00 per share. | SQUARER RON R | Director | — | 2025-06-03 00:00:00 | D |
| 7 | 40000 | — | — | Stock Award(Grant) at price 0.00 per share. | BIZZARI JEAN-PIERRE | Director | — | 2025-06-03 00:00:00 | D |
| 8 | 40000 | — | — | Stock Award(Grant) at price 0.00 per share. | SANDOR VICTOR | Director | — | 2025-06-03 00:00:00 | D |
| 9 | 40000 | — | — | Stock Award(Grant) at price 0.00 per share. | AZELBY ROBERT W | Director | — | 2025-06-03 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -16.80K | -10.92K | -3.48M | 2.97M |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.09 |
| NormalizedEBITDA | -102.57M | -145.78M | -91.12M | -265.33M |
| TotalUnusualItems | -80.00K | -52.00K | -16.57M | 34.80M |
| TotalUnusualItemsExcludingGoodwill | -80.00K | -52.00K | -16.57M | 34.80M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -157.85M | -240.05M | -157.13M | -230.03M |
| ReconciledDepreciation | 3.28M | 3.27M | 2.39M | 2.63M |
| ReconciledCostOfRevenue | 5.95M | 2.53M | 3.30M | 1.39M |
| EBITDA | -102.65M | -145.83M | -107.70M | -230.53M |
| EBIT | -105.92M | -149.09M | -110.09M | -233.16M |
| NetInterestIncome | -37.94M | -35.78M | -34.16M | -18.27M |
| InterestExpense | 50.21M | 46.33M | 36.73M | 18.34M |
| InterestIncome | 12.27M | 10.54M | 2.57M | 66.00K |
| NormalizedIncome | -157.78M | -240.01M | -144.04M | -261.85M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -157.85M | -240.05M | -157.13M | -230.03M |
| TotalExpenses | 200.43M | 234.61M | 332.89M | 295.27M |
| TotalOperatingIncomeAsReported | -130.65M | -165.99M | -123.34M | -261.72M |
| DilutedAverageShares | 97.16M | 81.71M | 78.15M | 76.68M |
| BasicAverageShares | 97.16M | 81.71M | 78.15M | 76.68M |
| DilutedEPS | -1.62 | -2.94 | -1.99 | -3.00 |
| BasicEPS | -1.62 | -2.94 | -1.99 | -3.00 |
| DilutedNIAvailtoComStockholders | -157.85M | -240.05M | -157.13M | -230.03M |
| NetIncomeCommonStockholders | -157.85M | -240.05M | -157.13M | -230.03M |
| NetIncome | -157.85M | -240.05M | -157.13M | -230.03M |
| NetIncomeIncludingNoncontrollingInterests | -157.85M | -240.05M | -157.13M | -230.03M |
| NetIncomeContinuousOperations | -157.85M | -240.05M | -157.13M | -230.03M |
| EarningsFromEquityInterestNetOfTax | -1.54M | -5.53M | -10.08M | |
| TaxProvision | 166.00K | 39.11M | 227.00K | -21.48M |
| PretaxIncome | -156.14M | -195.42M | -146.82M | -251.50M |
| OtherIncomeExpense | 11.39M | 5.42M | 10.33M | 28.12M |
| OtherNonOperatingIncomeExpenses | 11.47M | 5.47M | 26.91M | 366.00K |
| SpecialIncomeCharges | 0.00 | -42.11M | 0.00 | |
| OtherSpecialCharges | 42.11M | |||
| EarningsFromEquityInterest | -10.08M | -6.67M | ||
| GainOnSaleOfSecurity | -80.00K | -52.00K | 25.54M | 34.80M |
| NetNonOperatingInterestIncomeExpense | -37.94M | -35.78M | -34.16M | -18.27M |
| InterestExpenseNonOperating | 50.21M | 46.33M | 36.73M | 18.34M |
| InterestIncomeNonOperating | 12.27M | 10.54M | 2.57M | 66.00K |
| OperatingIncome | -129.59M | -165.05M | -122.99M | -261.35M |
| OperatingExpense | 194.48M | 232.08M | 329.59M | 293.88M |
| OtherTaxes | -1.06M | -935.00K | -357.00K | -366.00K |
| ResearchAndDevelopment | 109.63M | 127.13M | 186.46M | 158.00M |
| SellingGeneralAndAdministration | 85.91M | 105.89M | 143.49M | 136.24M |
| SellingAndMarketingExpense | 21.44M | 33.01M | 35.75M | 64.78M |
| GeneralAndAdministrativeExpense | 64.47M | 72.88M | 107.74M | 136.24M |
| OtherGandA | 17.68M | 20.54M | 25.98M | 50.30M |
| SalariesAndWages | 46.78M | 52.34M | 81.76M | 85.94M |
| GrossProfit | 64.89M | 67.03M | 206.61M | 32.52M |
| CostOfRevenue | 5.95M | 2.53M | 3.30M | 1.39M |
| TotalRevenue | 70.84M | 69.56M | 209.91M | 33.92M |
| OperatingRevenue | 70.84M | 69.56M | 209.91M | 33.92M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 2.74M | 6.75M | 8.40M | 1.46M |
| OrdinarySharesNumber | 98.86M | 82.29M | 80.64M | 76.81M |
| ShareIssued | 101.61M | 89.04M | 89.04M | 78.27M |
| TotalDebt | 123.00M | 124.38M | 117.38M | 139.70M |
| TangibleBookValue | -202.64M | -148.25M | 79.45M | 152.51M |
| InvestedCapital | -89.01M | -35.52M | 189.16M | 297.76M |
| WorkingCapital | 226.92M | 268.62M | 353.04M | 451.25M |
| NetTangibleAssets | -202.64M | -148.25M | 79.45M | 152.51M |
| CapitalLeaseObligations | 9.37M | 11.65M | 7.66M | 8.02M |
| CommonStockEquity | -202.64M | -148.25M | 79.45M | 166.09M |
| TotalCapitalization | -89.01M | -35.52M | 189.16M | 291.19M |
| TotalEquityGrossMinorityInterest | -202.64M | -148.25M | 79.45M | 166.09M |
| StockholdersEquity | -202.64M | -148.25M | 79.45M | 166.09M |
| GainsLossesNotAffectingRetainedEarnings | -1.42M | -93.00K | 1.82M | 102.83M |
| OtherEquityAdjustments | -1.42M | -93.00K | 1.82M | 102.65M |
| ForeignCurrencyTranslationAdjustments | -356.00K | 183.00K | ||
| TreasuryStock | 220.00K | 541.00K | 679.00K | 128.00K |
| RetainedEarnings | -1.49B | -1.34B | -1.10B | -924.88M |
| AdditionalPaidInCapital | 1.28B | 1.18B | 1.17B | 981.83M |
| CapitalStock | 8.43M | 7.31M | 7.31M | 6.45M |
| CommonStock | 8.43M | 7.31M | 7.31M | 6.45M |
| TotalLiabilitiesNetMinorityInterest | 524.62M | 503.03M | 411.41M | 451.88M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 444.15M | 435.36M | 329.47M | 377.95M |
| OtherNonCurrentLiabilities | 2.43M | 8.88M | 838.00K | |
| DerivativeProductLiabilities | 1.79M | 0.00 | ||
| EmployeeBenefits | 0.00 | 3.65M | ||
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 0.00 | 3.65M | ||
| NonCurrentDeferredLiabilities | 320.09M | 303.57M | 212.35M | 242.20M |
| NonCurrentDeferredRevenue | 23.54M | 23.54M | ||
| LongTermDebtAndCapitalLeaseObligation | 121.63M | 122.91M | 116.28M | 132.09M |
| LongTermCapitalLeaseObligation | 8.00M | 10.18M | 6.56M | 6.99M |
| LongTermDebt | 113.63M | 112.73M | 109.71M | 125.10M |
| CurrentLiabilities | 80.47M | 67.67M | 81.94M | 73.94M |
| OtherCurrentLiabilities | 26.95M | 13.04M | 16.56M | 14.11M |
| CurrentDebtAndCapitalLeaseObligation | 1.37M | 1.47M | 1.10M | 7.60M |
| CurrentCapitalLeaseObligation | 1.37M | 1.47M | 1.10M | 1.03M |
| CurrentDebt | 12.47M | 6.58M | ||
| OtherCurrentBorrowings | 12.47M | 6.58M | ||
| PayablesAndAccruedExpenses | 52.15M | 53.16M | 64.28M | 52.22M |
| CurrentAccruedExpenses | 34.12M | 37.59M | 51.93M | 36.38M |
| Payables | 18.03M | 15.57M | 12.35M | 15.83M |
| TotalTaxPayable | 0.00 | 3.75M | ||
| IncomeTaxPayable | 0.00 | 3.75M | ||
| AccountsPayable | 18.03M | 15.57M | 12.35M | 12.08M |
| TotalAssets | 321.98M | 354.78M | 490.86M | 617.97M |
| TotalNonCurrentAssets | 14.59M | 18.49M | 55.88M | 92.79M |
| OtherNonCurrentAssets | 1.16M | 711.00K | 902.00K | 693.00K |
| NonCurrentDeferredAssets | 0.00 | 37.10M | 26.05M | |
| NonCurrentDeferredTaxesAssets | 0.00 | 37.10M | 26.05M | |
| InvestmentsAndAdvances | 0.00 | 1.65M | 7.61M | 41.24M |
| LongTermEquityInvestment | 0.00 | 1.65M | 7.61M | 41.24M |
| InvestmentsinJointVenturesatCost | 0.00 | 1.65M | 7.61M | 41.24M |
| GoodwillAndOtherIntangibleAssets | 14.36M | 13.58M | ||
| OtherIntangibleAssets | 14.36M | 13.58M | ||
| NetPPE | 13.43M | 16.13M | 10.26M | 11.23M |
| AccumulatedDepreciation | -5.32M | -4.28M | -3.41M | -4.31M |
| GrossPPE | 18.75M | 20.41M | 13.67M | 15.54M |
| Leases | 3.87M | 3.95M | 2.08M | 11.25M |
| ConstructionInProgress | 0.00 | 0.00 | ||
| OtherProperties | 12.77M | 14.16M | 9.44M | 2.23M |
| MachineryFurnitureEquipment | 2.11M | 2.29M | 2.15M | 2.06M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 307.39M | 336.29M | 434.98M | 525.18M |
| OtherCurrentAssets | 9.45M | 5.99M | 23.50M | 1.56M |
| PrepaidAssets | 8.37M | 10.34M | 23.30M | 15.35M |
| Inventory | 18.39M | 16.18M | 12.07M | 11.12M |
| FinishedGoods | 49.00K | 82.00K | 16.00K | 560.00K |
| WorkInProcess | 18.34M | 16.09M | 12.06M | 10.56M |
| Receivables | 20.32M | 25.18M | 72.97M | 32.17M |
| OtherReceivables | 3.36M | 1.56M | ||
| TaxesReceivable | 763.00K | 387.00K | ||
| AccruedInterestReceivable | 619.00K | 0.00 | ||
| AccountsReceivable | 20.32M | 25.18M | 72.97M | 30.22M |
| CashCashEquivalentsAndShortTermInvestments | 250.87M | 278.60M | 326.44M | 466.54M |
| CashAndCashEquivalents | 250.87M | 278.60M | 326.44M | 466.54M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -124.70M | -121.90M | -139.00M | -239.75M |
| RepurchaseOfCapitalStock | -221.00K | 0.00 | ||
| RepaymentOfDebt | -1.01M | -977.00K | ||
| IssuanceOfDebt | 0.00 | 115.60M | 49.59M | |
| IssuanceOfCapitalStock | 60.51M | 0.00 | 6.13M | 0.00 |
| CapitalExpenditure | -867.00K | -3.22M | -687.00K | -6.38M |
| InterestPaidSupplementalData | 15.70M | 15.39M | 10.18M | |
| EndCashPosition | 250.87M | 278.60M | 326.44M | 466.54M |
| BeginningCashPosition | 278.60M | 326.44M | 466.54M | 439.19M |
| EffectOfExchangeRateChanges | -83.00K | 184.00K | -208.00K | 6.00K |
| ChangesInCash | -27.65M | -48.03M | -139.90M | 27.34M |
| FinancingCashFlow | 97.05M | 73.88M | -897.00K | 267.39M |
| CashFlowFromContinuingFinancingActivities | 97.05M | 73.88M | -897.00K | 267.39M |
| NetOtherFinancingCharges | -1.16M | 73.10M | -122.62M | 218.00M |
| ProceedsFromStockOptionExercised | 37.71M | 773.00K | 0.00 | 778.00K |
| NetCommonStockIssuance | 60.51M | 0.00 | 6.13M | 0.00 |
| CommonStockPayments | -221.00K | 0.00 | ||
| CommonStockIssuance | 60.51M | 0.00 | 6.13M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | 115.60M | 48.61M | |
| NetLongTermDebtIssuance | 0.00 | 115.60M | 48.61M | |
| LongTermDebtPayments | -1.01M | -977.00K | ||
| LongTermDebtIssuance | 0.00 | 115.60M | 49.59M | |
| InvestingCashFlow | -867.00K | -3.22M | -687.00K | -6.67M |
| CashFlowFromContinuingInvestingActivities | -867.00K | -3.22M | -687.00K | -6.67M |
| NetOtherInvestingChanges | -210.00K | -297.00K | ||
| NetIntangiblesPurchaseAndSale | -1.72M | -2.95M | ||
| PurchaseOfIntangibles | -1.72M | -2.95M | ||
| NetPPEPurchaseAndSale | -867.00K | -3.22M | -687.00K | -3.43M |
| PurchaseOfPPE | -867.00K | -3.22M | -687.00K | -3.43M |
| OperatingCashFlow | -123.83M | -118.69M | -138.31M | -233.38M |
| CashFlowFromContinuingOperatingActivities | -123.83M | -118.69M | -138.31M | -233.38M |
| TaxesRefundPaid | -13.47M | -671.00K | ||
| InterestReceivedCFO | 2.14M | 281.00K | ||
| InterestPaidCFO | -10.37M | -5.28M | ||
| ChangeInWorkingCapital | 3.83M | 44.27M | -48.73M | -15.71M |
| ChangeInOtherWorkingCapital | 1.85M | 4.57M | ||
| ChangeInOtherCurrentLiabilities | -8.88M | 5.67M | -1.20M | 12.52M |
| ChangeInOtherCurrentAssets | -1.94M | 7.49M | -11.67M | -6.36M |
| ChangeInPayablesAndAccruedExpense | 13.60M | -10.97M | 16.56M | 19.32M |
| ChangeInAccruedExpense | 11.14M | -14.14M | 16.25M | 12.52M |
| ChangeInPayable | 2.46M | 3.17M | 310.00K | 6.80M |
| ChangeInAccountPayable | 2.46M | 3.17M | 310.00K | 6.80M |
| ChangeInInventory | -3.73M | -5.71M | -9.65M | -3.02M |
| ChangeInReceivables | 4.77M | 47.79M | -42.75M | -30.22M |
| ChangesInAccountReceivables | 4.77M | 47.79M | -42.75M | -30.22M |
| OtherNonCashItems | 17.76M | 17.30M | -25.41M | -17.05M |
| StockBasedCompensation | 6.57M | 13.49M | 49.32M | 60.48M |
| AssetImpairmentCharge | 1.52M | 1.61M | 2.17M | -8.10M |
| DeferredTax | 0.00 | 37.10M | -1.62M | -26.05M |
| DeferredIncomeTax | 0.00 | 37.10M | -1.62M | -26.05M |
| DepreciationAmortizationDepletion | 3.28M | 3.27M | 2.39M | 2.63M |
| DepreciationAndAmortization | 3.28M | 3.27M | 2.39M | 2.63M |
| AmortizationCashFlow | 118.00K | 129.00K | ||
| AmortizationOfIntangibles | 118.00K | 129.00K | ||
| Depreciation | 3.28M | 3.27M | 2.39M | 2.50M |
| OperatingGainsLosses | 1.06M | 4.32M | 40.69M | 6.12M |
| PensionAndEmployeeBenefitExpense | -186.00K | -712.00K | 0.00 | -365.00K |
| EarningsLossesFromEquityInvestments | 1.54M | 5.53M | 10.08M | 6.67M |
| GainLossOnInvestmentSecurities | -296.00K | -497.00K | -11.50M | -34.89M |
| NetForeignCurrencyExchangeGainLoss | -107.00K | -185.00K | ||
| NetIncomeFromContinuingOperations | -157.85M | -240.05M | -157.13M | -230.03M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ADCT
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|